NCT04065698View on ClinicalTrials.gov

Pharmacokinetics and Safety of RV521 Formulations

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

August 13, 2019

Primary Completion Date

September 2, 2019

Study Completion Date

September 9, 2019

Conditions

Respiratory Syncytial Virus Infections

Interventions

DRUG

RV521

Single doses of RV521 administered as the drug in capsule formulation when fed and as the dry powder blend formulation dispersed in water when fed and whilst fasting, each on a separate dosing day.

Trial Locations (1)

SE1 1YR

Richmond Pharmacology Ltd, London